1. Interferon-β–Induced Pulmonary Arterial Hypertension
- Author
-
Marlowe W. Eldridge, Farhan Raza, James R. Runo, Theodore J. Berei, Naomi C. Chesler, Callyn Kozitza, Amy Chybowski, and Kara N. Goss
- Subjects
0301 basic medicine ,BP, blood pressure ,medicine.medical_specialty ,Dlco, diffusion capacity of carbon monoxide ,Case Report ,030105 genetics & heredity ,right ventricle ,World health ,BP - Blood pressure ,MS, multiple sclerosis ,03 medical and health sciences ,0302 clinical medicine ,Clinical Case ,Interferon β ,CMR, cardiac magnetic resonance ,Internal medicine ,pulmonary hypertension ,medicine ,IFN, interferon ,RHC, right-sided heart catheterization ,NYHA, New York Heart Association ,ET, endothelin ,BNP, B-type natriuretic peptide ,CPET, cardiopulmonary exercise test ,MS multiple sclerosis ,exercise ,business.industry ,Multiple sclerosis ,medicine.disease ,Pulmonary hypertension ,6MWD, 6-min walk distance ,PAH, pulmonary arterial hypertension ,Cardiology and Cardiovascular Medicine ,business ,RV, right ventricular ,030217 neurology & neurosurgery ,PA, pulmonary arterial - Abstract
A 48-year-old woman who had been receiving long-term interferon-β for 8 years for multiple sclerosis developed drug-induced World Health Organization group I pulmonary arterial hypertension. Triple therapy for pulmonary arterial hypertension and suspension of interferon-β led to improvement from a high-risk to low-risk state and improvement in exercise hemodynamics, including vascular distensibility, and right ventricle–pulmonary artery coupling. (Level of Difficulty: Advanced.), Central Illustration
- Published
- 2021